Yesterday evening an article was published in the local Antwerp newspaper GVA. It stated Flemish Minister of the Environment Jo Brouns (CD&V) has granted a permit for the Waterkracht project. As a result, all chemical companies in the Port of Antwerp will use purified wastewater to cool their production processes starting at the end of 2027. Earlier on the target was to start commercial operations early 2027 and this is still reflected in our earnings model. We will overhaul our model once it is...
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen
UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...
Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...
Friday during trading hours, UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine) for the treatment of pediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years. Following the positive CHMP opinion...
VGP NV: Voting Rights and Denominator Press ReleaseRegulated InformationAntwerp, 2 February 2026 – 07.00 a.m. CET In application of Article 15 of the Law of May 2, 2007 on the disclosure of major shareholdings in issuers whose shares are admitted for trading on a regulated market, VGP publishes, by means of a press release and on its website, the total share capital, the total number of securities with voting rights and the total number of voting rights at the latest at the end of each month in which any of these numbers has changed. Situation as at 31 January 2026: Total share capital:€...
VGP NV: Stemrechten en Noemer PersberichtGereglementeerde informatieAntwerpen, 2 februari 2026, 07:00 CET In toepassing van artikel 15 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt, publiceert VGP door middel van een persbericht en op haar website het totaal kapitaal, het totaal aantal stemrechtverlenende effecten en het totale aantal stemrechten uiterlijk op het einde van elke maand waarin één van deze aantallen is gewijzigd. Situatie op 31 Januari 2026: Totaal k...
VGP Announces Webcast to Review FY 2025 Financial Results on the 19th of February 2026 30 January 2026, Antwerp, Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, announces the details for the webcast to review its financial results for the year ended 31 December 2025: Thursday, 19 February 2026 at 10.30 a.m. (CET)Webcast link: The link above will allow you to register for the event. The presentation can be attended from your laptop, tablet or mobile device. The video will stream through your selected device. Plea...
VGP Kondigt Webcast aan voor Presentatie van de Resultaten over Boekjaar 2025 op 19 Februari 2026 30 Januari 2026, Antwerpen, België: VGP NV (‘VGP’ of ‘de Groep’), een pan-Europese aanbieder van hoogwaardig logistiek en semi-industrieel vastgoed, kondigt de details aan voor een webcast ter bespreking van de resultaten voor het boekjaar eindigend op 31 december 2025: Donderdag 19 februari 2026, om 10.30 a.m. (CET)Webcast link: Via bovenstaande link kunt u zich registreren voor het evenement. De presentatie kan worden bijgewoond vanaf uw laptop, tablet of mobiele telefoon. De video wordt...
Ahold Delhaize: Conditional approval for the acquisition of Delfood / Bekaert: Acquires Bridgestone's €80m tyre cord business in China and Thailand / KPN: In-line Q4, 2026 guidance, cash returns / NSI: Results in line, further vacancy weighing on 2026 and cautious tone on new developments / UCB: Cimzia included in Medicare's price negotiations for 2028
Ekopak just announced a long term strategic partnership with an unnamed European infrastructure partner for the development of (large) WaaS projects. Many details are still unknown and management was not (yet) available for comments. The partnership introduces a minimum of €150m in off balance sheet funding over the next three years that will be deployed through dedicated asset companies financed with senior non recourse debt and majority equity from the infrastructure partner. As part of the pa...
We reiterate our BUY rating on Colruyt but lower our target price from €44 to €38 following Colruyt's 1H25/26F results, which came in below expectations at the operating profit level. While we note management's confident tone during its conference call, we reduce our EBIT forecast by 3.6% for FY25/26F, implying that we now sit roughly 2% below company-guidance. We expect Sunday openings as of January 2026, as well as a strong price position in Belgium to benefit top-line growth over the next eig...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.